CAR T cell therapy has revolutionized cancer treatment, offering hope to patients with otherwise untreatable blood cancers. However, in Portugal these therapies are still produced abroad, creating long delays, high costs, and limited access for patients.

The CAR T-Matters project brings together Stemmatters, IPO Porto, and UCIBIO/LAQV at NOVA FCT to change this reality. By establishing, for the first time, the capacity to develop and manufacture CAR T therapies nationally, the consortium aims to make these treatments more accessible, affordable, and tailored to Portuguese patients.

This project represents a critical step toward building national expertise in advanced immunotherapies, reducing dependence on international facilities, and accelerating the arrival of innovative cancer treatments in Portugal.

An outstanding group of partners has been established to drive this project forward. Each member brings unique expertise and dedication, forming a collaborative team committed to achieving impactful results. Together, they contribute a wealth of knowledge and resources, ensuring the project’s success.